Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Non-Current Deffered Revenue (2024 - 2025)

Nuvation Bio (NUVB) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $145.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $145.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $145.8 million, a N/A change, with the full-year FY2025 number at $145.8 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $145.8 million for Q4 2025 at Nuvation Bio, up from $144.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $145.8 million in Q4 2025 to a low of $7.9 million in Q3 2024.